Adagrasib Data Create Buzz at ESMO.

Abstract

In phase I/II KRYSTAL-1 trial, the KRASG12C inhibitor adagrasib demonstrated encouraging clinical activity against metastatic colorectal cancer, both as a monotherapy and when combined with the EGFR inhibitor cetuximab. In patients who received adagrasib alone, the disease control rate was 87% and progression-free survival was 5.6 months. Among patients who received the drug combination, the disease control rate was 100%; data on progression-free survival were immature. The findings, along with data on the KRASG12C inhibitor sotorasib, were presented at the 2021 European Society for Medical Oncology Congress.

• Journal: Cancer discovery (Cancer Discov) Vol. 11 Issue 11 Pg. 2664 (11 2021) ISSN: 2159-8290 [Electronic] United States
• PMID: 34607832 (Publication Type: News)
• Copyright: ©2021 American Association for Cancer Research.